335 related articles for article (PubMed ID: 25624485)
21. Understanding SOS (Son of Sevenless).
Pierre S; Bats AS; Coumoul X
Biochem Pharmacol; 2011 Nov; 82(9):1049-56. PubMed ID: 21787760
[TBL] [Abstract][Full Text] [Related]
22. High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.
Burns MC; Howes JE; Sun Q; Little AJ; Camper DV; Abbott JR; Phan J; Lee T; Waterson AG; Rossanese OW; Fesik SW
Anal Biochem; 2018 May; 548():44-52. PubMed ID: 29444450
[TBL] [Abstract][Full Text] [Related]
23. A novel SOS1 mutation in Costello/CFC syndrome affects signaling in both RAS and PI3K pathways.
Tumurkhuu M; Saitoh M; Takita J; Mizuno Y; Mizuguchi M
J Recept Signal Transduct Res; 2013 Apr; 33(2):124-8. PubMed ID: 23528009
[TBL] [Abstract][Full Text] [Related]
24. Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo.
Huang S; Ren X; Wang L; Zhang L; Wu X
Cancer Prev Res (Phila); 2011 May; 4(5):666-73. PubMed ID: 21543344
[TBL] [Abstract][Full Text] [Related]
25. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
[TBL] [Abstract][Full Text] [Related]
26. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties.
Qian X; Esteban L; Vass WC; Upadhyaya C; Papageorge AG; Yienger K; Ward JM; Lowy DR; Santos E
EMBO J; 2000 Feb; 19(4):642-54. PubMed ID: 10675333
[TBL] [Abstract][Full Text] [Related]
27. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S
J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339
[TBL] [Abstract][Full Text] [Related]
28. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
29. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).
Ilinskaya ON; Singh I; Dudkina E; Ulyanova V; Kayumov A; Barreto G
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1559-67. PubMed ID: 27066977
[TBL] [Abstract][Full Text] [Related]
30. NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway.
Lin G; Tang Z; Ye YB; Chen Q
Oncol Rep; 2012 May; 27(5):1527-34. PubMed ID: 22327383
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
32. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
[TBL] [Abstract][Full Text] [Related]
33. miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells.
Liu Y; Zhang M; Qian J; Bao M; Meng X; Zhang S; Zhang L; Zhao R; Li S; Cao Q; Li P; Ju X; Lu Q; Li J; Shao P; Qin C; Yin C
DNA Cell Biol; 2015 Jun; 34(6):429-36. PubMed ID: 25811077
[TBL] [Abstract][Full Text] [Related]
34. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
35. SOS1 over-expression in genital skin fibroblasts from hirsute women: a putative role of the SOS1/RAS pathway in the pathogenesis of hirsutism.
Minella D; Wannenes F; Biancolella M; Amati F; Testa B; Nardone A; Bueno S; Fabbri A; Lauro D; Novelli G; Moretti C
J Biol Regul Homeost Agents; 2011; 25(4):615-26. PubMed ID: 22217993
[TBL] [Abstract][Full Text] [Related]
36. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
[TBL] [Abstract][Full Text] [Related]
37. Activation of Ras-dependent signaling pathways by G(14) -coupled receptors requires the adaptor protein TPR1.
Kwan DH; Yung LY; Ye RD; Wong YH
J Cell Biochem; 2012 Nov; 113(11):3486-97. PubMed ID: 22711498
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
[TBL] [Abstract][Full Text] [Related]
39. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
